In Johnson & Johnsonâ€™s Q3 2014 earnings call, the company reported strong performance with a 5.1% increase in worldwide sales and a significant 18.7% growth in the pharmaceutical segment, driven by new drug releases like OLYSIO. Despite challenges such as international market slowdown and competitive pressures in sectors like vision care and orthopedics, the company's emphasis on innovation and strategic investments promise continued growth. The reduced guidance impact due to OLYSIO sales in the forthcoming year is balanced by ongoing strategic growth plans and investment in high-growth areas. Thus, the stock may experience a positive impact in the short term due to this robust performance and optimistic guidance. 

[1]